Related Experiment Videos
DNA sequence recognition by bis-linked netropsin and distamycin derivatives
S L Grokhovsky1, A N Surovaya, G Burckhardt
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow.
FEBS Letters
|December 9, 1998
Summary
New platinum-based DNA-binding drugs show high affinity for specific AT-rich sequences. These compounds, cis-diammine Pt(II)-bridged bis-netropsin and bis-distamycin, offer enhanced sequence discrimination compared to parent molecules.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Biochemistry
Background:
- Netropsin and distamycin A are known DNA-binding molecules.
- Modifications to these molecules can alter their DNA interaction properties.
Purpose of the Study:
- To investigate the DNA binding interactions of novel platinum-bridged bis-netropsin and bis-distamycin compounds.
- To compare the sequence specificity of these novel compounds with their parent molecules.
Main Methods:
- DNase I footprinting assays to identify DNA binding sites.
- Circular dichroism (CD) spectroscopy to analyze DNA structural changes upon binding.
Main Results:
- cis-diammine Pt(II)-bridged bis-netropsin and bis-distamycin exhibit strong binding affinity for the 5'-TTTTAAAA-3' DNA sequence.
- These platinum-bridged compounds show reduced binding to the 5'-AAAATTTT-3' sequence.
- Parent compounds (netropsin, distamycin A) and oligomethylene-bridged bis-netropsin display significantly lower sequence discrimination.
Conclusions:
- Platinum-bridged bis-netropsin and bis-distamycin possess enhanced DNA sequence recognition capabilities.
- These findings suggest potential for developing sequence-specific DNA-targeting therapeutic agents.